%0 Journal Article
%T De
%A Adam Chahine
%A Ahmed Abdalla
%A Babikir Kheiri
%A Deepak L. Bhatt
%A Ghassan Bachuwa
%A Khansa Osman
%A Mohammed Osman
%A Mustafa Hassan
%A Sahar Ahmed
%J Journal of Cardiovascular Pharmacology and Therapeutics
%@ 1940-4034
%D 2019
%R 10.1177/1074248418809098
%X Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) are recommended to be placed on potent P2Y12 blockade. However, the long-term bleeding risk is high. Therefore, despite no definitive evidence, switching to clopidogrel beyond the acute phase is common. We aimed to evaluate the clinical outcomes of antiplatelet de-escalation compared with continuation in patients treated with PCI. We searched databases for randomized clinical trials (RCTs) that evaluated the safety and efficacy of antiplatelet de-escalation compared with continuation in patients treated with PCI. Pooled summary estimates were calculated. We included 3 RCTs with 3391 patients (median follow-up: 12 months). Compared with the continued group, the net clinical outcome (composite of bleeding or thrombotic events) was significantly reduced in the group switched to clopidogrel (8.7% vs 12.1%; risk ratio [RR]: 0.64; 95% confidence interval [CI]: 0.43-0.97; P = .03). However, there were similar clinical outcomes between groups for major adverse cardiovascular events (MACE; RR: 0.78; 95% CI: 0.55-1.11; P = .17), all Bleeding Academic Research Consortium (BARC) types bleeding (RR: 0.61; 95% CI: 0.33-1.11; P = .10), or BARC types ¡Ý2 bleeding (RR: 0.49; 95% CI: 0.19-1.26; P = .14). Our results suggest a net clinical benefit of de-escalation therapy shortly after PCI, without increased risk of MACE. Larger randomized trials will be necessary to confirm these findings
%K percutaneous coronary intervention
%K P2Y12
%K switch
%K de-escalation
%U https://journals.sagepub.com/doi/full/10.1177/1074248418809098